April 1st 2024
Throughout March, the FDA has approved drugs for the treatment of disease including lung, hematologic, esophageal, and gynecologic cancers.
The Latest on Acute Lymphocytic Leukemia
View More
A Focus on Acute Myeloid Leukemia
View More
Updates in Myelodysplastic Syndromes
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
PARP Inhibitor Resistance in Ovarian Cancer: We Need More Trials
November 3rd 2020While PARP inhibitors have played a large part in improving progression-free survival (PFS) in patients with ovarian cancer, long-term use of these agents often leads to resistance that are often quite challenging to overcome, according to Gottfried E. Konecny, MD.
Pembrolizumab Shows Modest Activity in Advanced Ovarian, Gynecologic Cancers
June 24th 2020Pembrolizumab (Keytruda) demonstrated modest clinical activity in patients with advanced recurrent ovarian cancer, according to final results of the phase 2 KEYNOTE-100 trial that were presented during the 2020 ASCO Virtual Scientific Program.
IMRT Betters Patient-Reported Outcomes in Cervical, Endometrial Cancer
May 5th 2020A reduction in patient-reported symptomatic adverse events (AEs) was observed with intensity-modulated radiotherapy (IMRT) compared with standard radiotherapy in patients with cervical or endometrial cancer, whereas no difference was observed with regard to clinician-reported AE.
FDA Grants Dual Immunotherapy Regimen a Fast Track Designation for Cervical Cancer
March 13th 2020The FDA has granted a Fast Track designation to the combination of the PD-1 inhibitor balstilimab and the CTLA-inhibitor zalifrelimab for the treatment of patients with relapsed or refractory metastatic cervical cancer.
FDA Approves Cytology Test to Improve Prevention of Cervical Cancer
March 11th 2020The FDA has approved the CINtec® PLUS Cytology test as the first biomarker-based triage test for women whose primary cervical cancer screening results are positive for the human papillomavirus (HPV) using the cobas® 4800 HPV Test, according to Roche (Genentech), the manufacturer of the test.
FDA Accepts Niraparib Application for Frontline Maintenance Ovarian Cancer Treatment
February 25th 2020The FDA has accepted a supplemental New Drug Application (sNDA) for niraparib (Zejula) for use as a frontline maintenance treatment for women with advanced ovarian cancer who responded to platinum-based chemotherapy regardless of biomarker status.
Establishing Medical Fitness is the First Step in Treating Patients with Advanced Ovarian Cancer
August 26th 2019Before considering intraperitoneal chemotherapy, or dose-dense chemotherapy, for newly diagnosed patients with advanced ovarian cancer, it's not vital to first determine whether the patient is medically fit for these treatments.
The Treatment Landscape for Recurrent Ovarian Cancer Is Evolving
August 25th 2019Chemotherapy is the foundation of treatment for patients with recurrent ovarian cancer, but according to Madeleine B. Courtney Brooks, MD, MPH, conversations regarding the potential for secondary debulking and use of bevacizumab (Avastin) may also be warranted.